Education
About Us
Working with TipRanks
Follow Us
MiNK Therapeutics (INKT)
NASDAQ:INKT
Total Valuation
MiNK Therapeutics has a market cap or net worth of $30.07M. The enterprise value is $27.93M.
Market Cap$30.07M
Enterprise Value$27.93M
Share Statistics
MiNK Therapeutics has 3.97M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding3.97M
Owened by Insiders3.12%
Owened by Instutions0.45%
Financial Efficiency
MiNK Therapeutics’s return on equity (ROE) is 550.64 and return on invested capital (ROIC) is 0.00%.
Return on Equity (ROE)55064.16%
Return on Assets (ROA)-188518.69%
Return on Invested Capital (ROIC)0.00%
Return on Capital Employed (ROCE)0.00%
Revenue Per Employee$0
Profits Per Employee-$468,904.435
Employee Count23
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of MiNK Therapeutics is -0.02. MiNK Therapeutics’s PEG ratio is >-0.01.
PE Ratio-0.02
PS Ratio0.00
PB Ratio-13.43
Price to Fair Value-13.43
Price to FCF-0.03
Price to Operating Cash Flow-0.03
PEG Ratio>-0.01
Income Statement
In the last 12 months, MiNK Therapeutics had revenue of $0.00 and earned -$10.78M in profits. Earnings per share was -$0.71.
Revenue$0.00
Gross Profit-$1.88B
Operating Income-$11.29M
Pretax Income-$10.78M
Net Income-$10.78M
EBITDA-10.62M
Earnings Per Share (EPS)-0.71
Cash Flow
In the last 12 months, operating cash flow was -$9.56M and capital expenditures $0.00, giving a free cash flow of -$9.56M billion.
Operating Cash Flow-$9.56M
Free Cash Flow-$9.56M
Free Cash Flow per Share-$2.41
Dividends & Yields
MiNK Therapeutics pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield-3633.25%
Earnings Yield-4100.67%
Stock Price Statistics
Beta1.18
52-Week Price Change-15.53%
50-Day Moving Average8.97
200-Day Moving Average8.08
Relative Strength Index (RSI)55.03
Average Volume (3m)8.90K
Important Dates
MiNK Therapeutics upcoming earnings date is May 7, 2025, Before Open.
Last Earnings DateMar 18, 2025
Next Earnings DateMay 7, 2025
Ex-Dividend Date―
Financial Position
MiNK Therapeutics as a current ratio of 716.68, with Debt / Equity ratio of -0.25
Current Ratio716.68
Quick Ratio716.68
Debt to Market Cap0.02
Net Debt to EBITDA0.00
Interest Coverage Ratio0.00
Taxes
In the past 12 months, MiNK Therapeutics has paid -$1.00 in taxes.
Income Tax-$1.00
Effective Tax Rate0.00%
Enterprise Valuation
MiNK Therapeutics EV to EBITDA ratio is 0.00, with an EV/FCF ratio of -0.03.
EV to Sales0.00
EV to EBITDA0.00
EV to Free Cash Flow-0.03
EV to Operating Cash Flow-0.03
Balance Sheet
MiNK Therapeutics has $4.58M in cash and marketable securities with $4.92M in debt, giving a net cash position of $347.57K billion.
Cash & Marketable Securities$4.58M
Total Debt$4.92M
Net Cash$347.57K
Net Cash Per Share$0.09
Tangible Book Value Per Share-$0.52
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for MiNK Therapeutics is $21.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$21.00
Price Target Upside177.04%
Analyst ConsensusStrong Buy
Analyst Count3
Revenue Growth Forecast
EPS Growth Forecast55.52%